Literature DB >> 29362953

Chronic coffee consumption and striatal DAT-SPECT findings in Parkinson's disease.

Angelo Fabio Gigante1, Artor Niccoli Asabella2, Giovanni Iliceto1, Tommaso Martino3, Cristina Ferrari2, Giovanni Defazio1,4, Giuseppe Rubini2.   

Abstract

Coffee may interfere with the dopaminergic transmission, and this action would possibly enhance motor activity and exert an antidyskinetic effect in Parkinson's disease (PD). This study aimed to see whether coffee habit could be associated with change in striatal dopamine active transporter (DAT)-single photon emission computed tomography (SPECT) imaging in PD. A total of 83 PD patients (71 current coffee drinkers and 12 never drinkers) underwent a DAT-SPECT study, using [123I]FP-CIT as radionuclide. Socio-demographic and clinical information as well as smoking habit was collected at the time of imaging acquisition. The Unified Parkinson's Disease Rating Scale part III was used to evaluate disease severity. On multivariable analysis, chronic coffee consumption was not associated with any significant change in striatal uptake of the radionuclide. However, the number of years patients drunk coffee was correlated with a significant increase in age at PD onset (p < 0.001). Confirming a previous report, current cigarette smoking was associated with a reduction of radionuclide uptake in putamen and caudate (p < 0.001).

Entities:  

Keywords:  Coffee; DAT scan; Nicotine; Parkinson’s disease

Mesh:

Substances:

Year:  2018        PMID: 29362953     DOI: 10.1007/s10072-018-3253-1

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  30 in total

Review 1.  Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.

Authors:  Michael A Schwarzschild; Kui Xu; Emin Oztas; Jacobus P Petzer; Kay Castagnoli; Neal Castagnoli; Jiang-Fan Chen
Journal:  Neurology       Date:  2003-12-09       Impact factor: 9.910

2.  A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease.

Authors:  Miguel A Hernán; Bahi Takkouche; Francisco Caamaño-Isorna; Juan J Gestal-Otero
Journal:  Ann Neurol       Date:  2002-09       Impact factor: 10.422

3.  Role of adenosine A1 receptors in the modulation of dopamine D1 and adenosine A2A receptor signaling in the neostriatum.

Authors:  K Yabuuchi; M Kuroiwa; T Shuto; N Sotogaku; G L Snyder; H Higashi; M Tanaka; P Greengard; A Nishi
Journal:  Neuroscience       Date:  2006-06-05       Impact factor: 3.590

4.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

Review 5.  Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson's disease.

Authors:  Jacobus P Petzer; Anel Petzer
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

Review 6.  The role and regulation of adenosine in the central nervous system.

Authors:  T V Dunwiddie; S A Masino
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

7.  Midbrain SERT in degenerative parkinsonisms: a 123I-FP-CIT SPECT study.

Authors:  Francesco Roselli; Nicola M Pisciotta; Michele Pennelli; Maria S Aniello; Angelo Gigante; Maria F De Caro; Ermanno Ferrannini; Bruno Tartaglione; Artor Niccoli-Asabella; Giovanni Defazio; Paolo Livrea; Giuseppe Rubini
Journal:  Mov Disord       Date:  2010-09-15       Impact factor: 10.338

8.  123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.

Authors:  A Antonini; R Benti; R De Notaris; S Tesei; A Zecchinelli; G Sacilotto; N Meucci; M Canesi; C Mariani; G Pezzoli; P Gerundini
Journal:  Neurol Sci       Date:  2003-10       Impact factor: 3.307

9.  Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells.

Authors:  Kazuhiro Nakaso; Satoru Ito; Kenji Nakashima
Journal:  Neurosci Lett       Date:  2007-12-23       Impact factor: 3.046

10.  Caffeine drinking, cigarette smoking, and dopaminergic replacement therapy dose in Parkinson's disease.

Authors:  Carmen Ojeda-López; Amin Cervantes-Arriaga; Mayela Rodríguez-Violante; Teresa Corona
Journal:  Neurol Sci       Date:  2012-09-07       Impact factor: 3.307

View more
  5 in total

1.  Coffee, smoking and aspirin are associated with age at onset in idiopathic Parkinson's disease.

Authors:  Carolin Gabbert; Inke R König; Theresa Lüth; Beke Kolms; Meike Kasten; Eva-Juliane Vollstedt; Alexander Balck; Anne Grünewald; Christine Klein; Joanne Trinh
Journal:  J Neurol       Date:  2022-03-02       Impact factor: 6.682

Review 2.  Molecular Imaging of the Dopamine Transporter.

Authors:  Giovanni Palermo; Roberto Ceravolo
Journal:  Cells       Date:  2019-08-10       Impact factor: 6.600

Review 3.  Beneficial Effects of Epigallocatechin-3-O-Gallate, Chlorogenic Acid, Resveratrol, and Curcumin on Neurodegenerative Diseases.

Authors:  Ryuuta Fukutomi; Tomokazu Ohishi; Yu Koyama; Monira Pervin; Yoriyuki Nakamura; Mamoru Isemura
Journal:  Molecules       Date:  2021-01-14       Impact factor: 4.411

Review 4.  Addressing the Neuroprotective Actions of Coffee in Parkinson's Disease: An Emerging Nutrigenomic Analysis.

Authors:  Lai Kuan Lee; Nur Anis Raihana Mhd Rodzi
Journal:  Antioxidants (Basel)       Date:  2022-08-16

Review 5.  Knowing Your Beans in Parkinson's Disease: A Critical Assessment of Current Knowledge about Different Beans and Their Compounds in the Treatment of Parkinson's Disease and in Animal Models.

Authors:  Michel Rijntjes
Journal:  Parkinsons Dis       Date:  2019-10-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.